Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Germany

Umckaloabo Patents Challenged

May 2008 | Company News Alert

Highlighting the legal minefield of bioprospecting, Germany's Schwabe Pharmaceuticals is facing a challenge to two European Patent Office (EPO) patents for its phytopharmaceutical Umckaloabo, which is extracted from the root of South Africa's Pelargonium sidoides plant. Swiss non-governmental organisation (NGO) Berne Declaration and the African Centre for Biosafety (ACB) are assisting a local community in South Africa to challenge patents relating to

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *

Forgotten your password?

If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.

Free Trial To Pharmaceuticals & Healthcare Insight

TAKE A TRIAL >>
Related Insight Articles
Enaleni Rose To The Challenge In 2007

Companies / South Africa In the company's own words, Enaleni's recently released annual results for the year ending December 31 2007 were 'reasonable, under the circumstances'. BMI would agree with this assessment. Revenues...
March 2008
Teva, Mylan Compete For Merck KGaA's Generics Arm

Companies / Germany The race for the generics business of Germany's Merck KGaA looks to be heading into the final stages with two firms thought to be leading the bidding - Israel's Teva , and US-based Mylan. At...
May 2007
Merck KGaA To Divest Generics Business?

Companies / Germany German drugmaker
January 2007
Aspen Announces Strong Results

Companies / South Africa South African generics maker Aspen has announced operating profits of ZAR473.8mn (US$77.56mn) for the six months to December 2005, an increase of 34% year-on-year. The strong results were driven primarily...
March 2006
Lupin To Form Joint Venture With Aspen

Companies / South Africa Indian drugmaker Lupin has agreed a deal with South African generics firm Aspen to form a 50:50 joint venture to develop, manufacture and market TB drugs. The JV will also investigate the possibilities...
March 2006
Middle East & Africa InsightMiddle East & Africa Channels Middle East & Africa Countries


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2008 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS